ARL6IP5 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the Jurkat human T-lymphocyte line, engineered for loss-of-function studies of the ARL6IP5 gene. This knockout model, generated by CRISPR/Cas9-mediated gene disruption, provides a genetically heterogeneous pool of Jurkat cells carrying targeted mutations in the ARL6IP5 locus, enabling robust functional genomics analyses without clonal selection.
The Jurkat cell line is an immortalized human T-cell line originally established from a patient with acute T-cell leukemia. Growing in suspension, these cells are widely employed as a model system for T-cell receptor (TCR) signaling, apoptosis regulation, and leukemogenesis. Their lymphoblastoid phenotype and well-characterized signaling pathways make them particularly suitable for dissecting molecular mechanisms in hematopoietic malignancies and immune cell function.
ARL6IP5 (also known as JWA) is a multifunctional protein that participates in intracellular vesicular trafficking and stress responses. It forms complexes with ARL6 and PRA1 (PRAF2) to coordinate protein transport, and it modulates cytoskeletal dynamics through interactions with actin and integrin ??3. Upstream, ARL6IP5 expression is regulated by phorbol esters (PMA) and the MAPK pathway, as well as by oxidative stress cues. Downstream, ARL6IP5 influences apoptosis by regulating Bcl-2 family proteins, and it impacts cell adhesion and migration via integrin ??3 expression. Its involvement in MAPK signaling and oxidative stress responses positions ARL6IP5 at the intersection of trafficking, survival, and cytoskeletal reorganization.
In Jurkat cells, ARL6IP5 disruption allows researchers to investigate how alterations in vesicular transport and integrin-mediated adhesion affect T-cell receptor signaling and apoptotic thresholds. Given the cell line??s origin from a leukemia, this knockout model is particularly relevant for exploring chemoresistance mechanisms. The polyclonal nature of the edited population mirrors the heterogeneity often observed in tumor cell populations, offering a more physiologically relevant substrate for studying pathway dependencies compared to single-cell-derived clones.
Typical experimental applications include flow cytometric assessment of apoptosis using Annexin V/PI staining, Western blot analysis of ARL6IP5, Bcl-2 family members, and integrin ??3, and RT-qPCR for transcriptional profiling. Cell viability assays such as MTT can evaluate drug sensitivity, while migration assays probe cytoskeletal and integrin function. Co-immunoprecipitation experiments can confirm protein interactions with ARL6, PRA1, or CLIC1. This knockout tool is suited for studies in T-cell biology, leukemia drug resistance, and protein trafficking. For further information or technical support, please contact Ascent Research.
